|
US975286A
(en)
*
|
1910-03-05 |
1910-11-08 |
Charles H A F L Ross |
Trigger mechanism.
|
|
GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
|
US3868358A
(en)
|
1971-04-30 |
1975-02-25 |
Lilly Co Eli |
Protamine-insulin product
|
|
US3758683A
(en)
|
1971-04-30 |
1973-09-11 |
R Jackson |
Insulin product
|
|
US4153689A
(en)
|
1975-06-13 |
1979-05-08 |
Takeda Chemical Industries, Ltd. |
Stable insulin preparation for nasal administration
|
|
GB1554157A
(en)
|
1975-06-13 |
1979-10-17 |
Takeda Chemical Industries Ltd |
Stable insulin preparation for intra nasal administration
|
|
GB1527605A
(en)
|
1975-08-20 |
1978-10-04 |
Takeda Chemical Industries Ltd |
Insulin preparation for intranasal administration
|
|
US4165370A
(en)
|
1976-05-21 |
1979-08-21 |
Coval M L |
Injectable gamma globulin
|
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
|
|
DE3064888D1
(en)
|
1979-04-30 |
1983-10-27 |
Hoechst Ag |
Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
|
|
US4783441A
(en)
|
1979-04-30 |
1988-11-08 |
Hoechst Aktiengesellschaft |
Aqueous protein solutions stable to denaturation
|
|
JPS55153712A
(en)
|
1979-05-18 |
1980-11-29 |
Kao Corp |
Insulin pharmaceutical preparation and its production
|
|
DE3033127A1
(de)
|
1980-09-03 |
1982-04-08 |
Hoechst Ag, 6000 Frankfurt |
Neue analoga des insulins
|
|
US4367737A
(en)
|
1981-04-06 |
1983-01-11 |
George Kozam |
Multiple barrel syringe
|
|
JPS58501125A
(ja)
|
1981-07-17 |
1983-07-14 |
ノルデイスク・インスリンラボラトリウム |
安定な水性治療性インシユリン製剤及びその製造方法
|
|
NL193099C
(nl)
|
1981-10-30 |
1998-11-03 |
Novo Industri As |
Gestabiliseerde insuline-oplossing.
|
|
DE3326472A1
(de)
|
1983-07-22 |
1985-02-14 |
Hoechst Ag, 6230 Frankfurt |
Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
|
|
DE3326473A1
(de)
|
1983-07-22 |
1985-01-31 |
Hoechst Ag, 6230 Frankfurt |
Pharmazeutisches mittel zur behandlung des diabetes mellitus
|
|
DE3327709A1
(de)
|
1983-07-29 |
1985-02-07 |
Hoechst Ag, 6230 Frankfurt |
Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
|
|
DE3333640A1
(de)
|
1983-09-17 |
1985-04-25 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
|
|
US4839341A
(en)
|
1984-05-29 |
1989-06-13 |
Eli Lilly And Company |
Stabilized insulin formulations
|
|
CA1244347A
(en)
|
1984-05-29 |
1988-11-08 |
Eddie H. Massey |
Stabilized insulin formulations
|
|
EP0166971B1
(de)
|
1984-06-09 |
1990-02-28 |
Hoechst Aktiengesellschaft |
Insulinzubereitungen, Verfahren zu deren Herstellung und deren Verwendung
|
|
DE3440988A1
(de)
|
1984-11-09 |
1986-07-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
|
|
US5008241A
(en)
|
1985-03-12 |
1991-04-16 |
Novo Nordisk A/S |
Novel insulin peptides
|
|
DK347086D0
(da)
|
1986-07-21 |
1986-07-21 |
Novo Industri As |
Novel peptides
|
|
DK113585D0
(da)
|
1985-03-12 |
1985-03-12 |
Novo Industri As |
Nye peptider
|
|
IL78425A
(en)
|
1985-04-15 |
1991-05-12 |
Lilly Co Eli |
Intranasal formulation containing insulin
|
|
US4689042A
(en)
|
1985-05-20 |
1987-08-25 |
Survival Technology, Inc. |
Automatic medicament ingredient mixing and injecting apparatus
|
|
DE3526995A1
(de)
|
1985-07-27 |
1987-02-05 |
Hoechst Ag |
Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
|
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
|
US4960702A
(en)
|
1985-09-06 |
1990-10-02 |
Codon |
Methods for recovery of tissue plasminogen activator
|
|
US5496924A
(en)
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
|
DE3541856A1
(de)
|
1985-11-27 |
1987-06-04 |
Hoechst Ag |
Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
|
|
DE3636903A1
(de)
|
1985-12-21 |
1987-07-02 |
Hoechst Ag |
Fusionsproteine mit eukaryotischem ballastanteil
|
|
CA1275922C
(en)
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Treatment of cancer
|
|
DE3544295A1
(de)
|
1985-12-14 |
1987-06-19 |
Bayer Ag |
Thermoplastische formmassen mit hoher kriechstromfestigkeit
|
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
PH23446A
(en)
|
1986-10-20 |
1989-08-07 |
Novo Industri As |
Peptide preparations
|
|
CA1339416C
(en)
|
1987-02-25 |
1997-09-02 |
Liselotte Langkjaer |
Insulin derivatives
|
|
US5034415A
(en)
|
1987-08-07 |
1991-07-23 |
Century Laboratories, Inc. |
Treatment of diabetes mellitus
|
|
DE3726655A1
(de)
|
1987-08-11 |
1989-02-23 |
Hoechst Ag |
Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
|
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
|
US6875589B1
(en)
|
1988-06-23 |
2005-04-05 |
Hoechst Aktiengesellschaft |
Mini-proinsulin, its preparation and use
|
|
DE3827533A1
(de)
|
1988-08-13 |
1990-02-15 |
Hoechst Ag |
Pharmazeutische zubereitung zur behandlung des diabetes mellitus
|
|
US4923162A
(en)
|
1988-09-19 |
1990-05-08 |
Fleming Matthew C |
Radiation shield swivel mount
|
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
|
US5225323A
(en)
|
1988-11-21 |
1993-07-06 |
Baylor College Of Medicine |
Human high-affinity neurotransmitter uptake system
|
|
KR910700262A
(ko)
|
1988-12-23 |
1991-03-14 |
안네 제케르 |
사람 인슐린 유사체
|
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
|
US5514646A
(en)
|
1989-02-09 |
1996-05-07 |
Chance; Ronald E. |
Insulin analogs modified at position 29 of the B chain
|
|
PT93057B
(pt)
|
1989-02-09 |
1995-12-29 |
Lilly Co Eli |
Processo para a preparacao de analogos da insulina
|
|
DK134189D0
(da)
|
1989-03-20 |
1989-03-20 |
Nordisk Gentofte |
Insulinforbindelser
|
|
EP0471036B2
(en)
|
1989-05-04 |
2004-06-23 |
Southern Research Institute |
Encapsulation process
|
|
US5358857A
(en)
|
1989-08-29 |
1994-10-25 |
The General Hospital Corp. |
Method of preparing fusion proteins
|
|
GR1005153B
(el)
|
1989-08-29 |
2006-03-13 |
The General Hospital Corporation |
Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
|
|
US5227293A
(en)
|
1989-08-29 |
1993-07-13 |
The General Hospital Corporation |
Fusion proteins, their preparation and use
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
|
US5397771A
(en)
|
1990-05-10 |
1995-03-14 |
Bechgaard International Research And Development A/S |
Pharmaceutical preparation
|
|
ATE164080T1
(de)
|
1990-05-10 |
1998-04-15 |
Bechgaard Int Res |
Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
|
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
|
DK10191D0
(da)
|
1991-01-22 |
1991-01-22 |
Novo Nordisk As |
Hidtil ukendte peptider
|
|
US5272135A
(en)
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
|
CA2038597A1
(en)
|
1991-03-19 |
1992-09-20 |
Jose P. Garzaran |
A method and a pharmaceutical preparation for treating pain
|
|
US6468959B1
(en)
|
1991-12-05 |
2002-10-22 |
Alfatec-Pharm Gmbh |
Peroral dosage form for peptide containing medicaments, in particular insulin
|
|
US5614219A
(en)
|
1991-12-05 |
1997-03-25 |
Alfatec-Pharma Gmbh |
Oral administration form for peptide pharmaceutical substances, in particular insulin
|
|
US5197926A
(en)
|
1992-02-18 |
1993-03-30 |
Hedstrom Corporation |
Swing connection guard
|
|
CH682806A5
(de)
|
1992-02-21 |
1993-11-30 |
Medimpex Ets |
Injektionsgerät.
|
|
CH682805A5
(de)
|
1992-02-24 |
1993-11-30 |
Medimpex Ets |
Anzeigeeinrichtung für ein Injektionsgerät.
|
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US5253785A
(en)
|
1992-04-02 |
1993-10-19 |
Habley Medical Technology Corp. |
Variable proportion dispenser
|
|
SG46612A1
(en)
|
1992-12-02 |
1998-02-20 |
Hoechst Ag |
Process for obtaining proinsulin in processing correctly linked cystine bridges
|
|
AU680462B2
(en)
|
1992-12-18 |
1997-07-31 |
Eli Lilly And Company |
Insulin analogs
|
|
US5358708A
(en)
|
1993-01-29 |
1994-10-25 |
Schering Corporation |
Stabilization of protein formulations
|
|
US5478323A
(en)
|
1993-04-02 |
1995-12-26 |
Eli Lilly And Company |
Manifold for injection apparatus
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
ATE176482T1
(de)
|
1993-06-21 |
1999-02-15 |
Novo Nordisk As |
Asp-b28-insulinkristalle
|
|
US5506203C1
(en)
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
|
US5534488A
(en)
|
1993-08-13 |
1996-07-09 |
Eli Lilly And Company |
Insulin formulation
|
|
EP2275089A1
(en)
|
1993-11-19 |
2011-01-19 |
Alkermes Controlled Therapeutics, Inc. |
Preparation of biodegradable microparticles containing a biologically active agent
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
IT1265271B1
(it)
|
1993-12-14 |
1996-10-31 |
Alcatel Italia |
Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
DE4405179A1
(de)
|
1994-02-18 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
|
|
DE4405388A1
(de)
|
1994-02-19 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
|
|
ATE264096T1
(de)
|
1994-03-07 |
2004-04-15 |
Nektar Therapeutics |
Verfahren und mittel zur verabreichung von insulin über die lunge
|
|
US5474978A
(en)
|
1994-06-16 |
1995-12-12 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5559094A
(en)
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
|
BR9509201A
(pt)
|
1994-09-09 |
1997-12-30 |
Takeda Chemical Industries Ltd |
Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada
|
|
US5879584A
(en)
|
1994-09-10 |
1999-03-09 |
The Procter & Gamble Company |
Process for manufacturing aqueous compositions comprising peracids
|
|
US5547929A
(en)
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5766582A
(en)
|
1994-10-11 |
1998-06-16 |
Schering Corporation |
Stable, aqueous alfa interferon solution formulations
|
|
US5707641A
(en)
|
1994-10-13 |
1998-01-13 |
Pharmaderm Research & Development Ltd. |
Formulations comprising therapeutically-active proteins or polypeptides
|
|
YU18596A
(sh)
|
1995-03-31 |
1998-07-10 |
Eli Lilly And Company |
Analogne formulacije monomernog insulina
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
AU5724996A
(en)
|
1995-05-05 |
1996-11-21 |
Eli Lilly And Company |
Single chain insulin with high bioactivity
|
|
US5824638A
(en)
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
WO1996041606A2
(en)
|
1995-06-08 |
1996-12-27 |
Therexsys Limited |
Improved pharmaceutical compositions for gene therapy
|
|
DE69632684T2
(de)
|
1995-06-27 |
2005-06-09 |
Takeda Pharmaceutical Co. Ltd. |
Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
|
|
JPH11292787A
(ja)
|
1995-08-15 |
1999-10-26 |
Asahi Chem Ind Co Ltd |
生理活性ペプチドを含有する経粘膜投与製剤
|
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
|
DK0915910T3
(da)
|
1996-06-05 |
2006-05-22 |
Roche Diagnostics Gmbh |
Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
|
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
|
WO1997048413A1
(en)
|
1996-06-20 |
1997-12-24 |
Novo Nordisk A/S |
Insulin preparations containing carbohydrates
|
|
KR100451778B1
(ko)
|
1996-06-20 |
2004-11-16 |
노보 노르디스크 에이/에스 |
Nacl을함유하는인슐린제제
|
|
US5948751A
(en)
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
|
JP2001501593A
(ja)
|
1996-08-08 |
2001-02-06 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
胃腸運動を調節するための方法
|
|
AU752411B2
(en)
|
1996-08-13 |
2002-09-19 |
Genentech Inc. |
Formulation
|
|
US5783556A
(en)
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
|
ES2283025T3
(es)
|
1996-08-30 |
2007-10-16 |
Novo Nordisk A/S |
Derivados de glp-1.1.
|
|
US6384016B1
(en)
|
1998-03-13 |
2002-05-07 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
EP1629849B2
(en)
|
1997-01-07 |
2017-10-04 |
Amylin Pharmaceuticals, LLC |
Pharmaceutical compositions comprising exendins and agonists thereof
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
EP0981611A1
(en)
|
1997-02-05 |
2000-03-01 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
|
US6043214A
(en)
|
1997-03-20 |
2000-03-28 |
Novo Nordisk A/S |
Method for producing powder formulation comprising an insulin
|
|
RU2198181C2
(ru)
|
1997-03-20 |
2003-02-10 |
Ново Нордиск А/С |
Не содержащие цинк кристаллы инсулина для применения в легочных композициях
|
|
US6310038B1
(en)
|
1997-03-20 |
2001-10-30 |
Novo Nordisk A/S |
Pulmonary insulin crystals
|
|
AR012894A1
(es)
|
1997-06-13 |
2000-11-22 |
Lilly Co Eli |
Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
|
|
DK0999853T3
(da)
|
1997-06-13 |
2003-04-22 |
Genentech Inc |
Stabiliseret antostofformulering
|
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
|
CA2299425A1
(en)
|
1997-08-08 |
1999-02-18 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
DE19735711C2
(de)
|
1997-08-18 |
2001-04-26 |
Aventis Pharma Gmbh |
Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
|
|
TR200001050T2
(tr)
|
1997-10-24 |
2000-08-21 |
Eli Lilly And Company |
Çözünmez insülin bileşimleri
|
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
|
AU1375199A
(en)
|
1997-11-12 |
1999-05-31 |
Alza Corporation |
Method for decreasing self-association of polypeptides
|
|
PT1032587E
(pt)
|
1997-11-14 |
2008-04-21 |
Amylin Pharmaceuticals Inc |
Novos compostos agonistas de exendina
|
|
NZ504258A
(en)
|
1997-11-14 |
2002-12-20 |
Amylin Pharmaceuticals Inc |
Exendin 3 and 4 agonist compounds for the treatment of diabetes
|
|
AU1617399A
(en)
|
1997-12-05 |
1999-06-28 |
Eli Lilly And Company |
Glp-1 formulations
|
|
DE69924232D1
(de)
|
1998-01-09 |
2005-04-21 |
Novo Nordisk As |
Stabilisierte insulin-zubereitungen
|
|
CA2320371C
(en)
|
1998-02-13 |
2012-01-17 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
|
EP1056776A1
(en)
|
1998-02-23 |
2000-12-06 |
Neurocrine Biosciences, Inc. |
Methods for treatment of diabetes using peptide analogues of insulin
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1950224A3
(en)
|
1998-03-09 |
2008-12-17 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
DE69939900D1
(de)
|
1998-06-05 |
2008-12-24 |
Nutrinia Ltd |
Insulin angereichertes säuglingsnährpräparat
|
|
AU6294899A
(en)
|
1998-10-07 |
2000-04-26 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
PL197504B1
(pl)
|
1998-10-16 |
2008-04-30 |
Novo Nordisk As |
Trwałe stężone preparaty insulinowe do podawania do płuc
|
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
|
CA2346884A1
(en)
|
1998-10-16 |
2000-04-27 |
Novo Nordisk A/S |
Insulin preparations for pulmonary delivery containing menthol
|
|
US6489292B1
(en)
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
|
JP2002529514A
(ja)
|
1998-11-18 |
2002-09-10 |
ノボ ノルディスク アクティーゼルスカブ |
フェノール及びクレゾールを要さない安定なインスリン水性調製物
|
|
AU777564B2
(en)
|
1999-01-14 |
2004-10-21 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist formulations and methods of administration thereof
|
|
DE19908041A1
(de)
|
1999-02-24 |
2000-08-31 |
Hoecker Hartwig |
Kovalent verbrückte Insulindimere
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
US6227819B1
(en)
|
1999-03-29 |
2001-05-08 |
Walbro Corporation |
Fuel pumping assembly
|
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
|
WO2000066629A1
(en)
|
1999-04-30 |
2000-11-09 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6329336B1
(en)
|
1999-05-17 |
2001-12-11 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
|
EP1187639A1
(en)
|
1999-06-04 |
2002-03-20 |
Delrx Pharmaceutical Corporation |
Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
AU5760900A
(en)
|
1999-06-25 |
2001-01-31 |
Minimed, Inc. |
Multiple agent diabetes therapy
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
DE19930631A1
(de)
|
1999-07-02 |
2001-01-11 |
Clemens Micheler |
Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
DE60020382T2
(de)
|
1999-09-21 |
2006-01-26 |
Skyepharma Canada Inc., Verdun |
Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
|
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
|
CN100389821C
(zh)
|
1999-10-04 |
2008-05-28 |
希龙公司 |
稳定化的含多肽的液体药物组合物
|
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
|
SK287810B6
(sk)
|
1999-11-03 |
2011-10-04 |
Bristol-Myers Squibb Company |
Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu
|
|
EP1523993A1
(en)
|
1999-12-16 |
2005-04-20 |
Eli Lilly & Company |
Polypeptide compositions with improved stability
|
|
PT1242121E
(pt)
|
1999-12-16 |
2005-05-31 |
Lilly Co Eli |
Composicoes polipeptidicas com estabilidade melhorada
|
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
|
EP1250126A2
(en)
|
2000-01-11 |
2002-10-23 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
|
US20010012829A1
(en)
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
|
WO2001052937A1
(en)
|
2000-01-24 |
2001-07-26 |
Medtronic Minimed, Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
AU2001264789A1
(en)
|
2000-06-08 |
2001-12-17 |
Eli Lilly And Company |
Protein powder for pulmonary delivery
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
EP1303532A2
(en)
|
2000-07-12 |
2003-04-23 |
Eli Lilly And Company |
Process to increase protein stability
|
|
ATE396738T1
(de)
|
2000-09-18 |
2008-06-15 |
Sanos Bioscience As |
Verwendung von glp-2-peptiden
|
|
KR100508695B1
(ko)
|
2001-02-13 |
2005-08-17 |
한국과학기술연구원 |
인슐린의 경구투여용 제형과 그의 제조방법
|
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
|
DE10108100A1
(de)
|
2001-02-20 |
2002-08-29 |
Aventis Pharma Gmbh |
Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
|
|
DE10108211A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
|
|
DE10108212A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
|
|
WO2002067969A2
(en)
|
2001-02-21 |
2002-09-06 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
|
WO2002067868A2
(en)
|
2001-02-26 |
2002-09-06 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of metabolic disorders, including obesity and diabetes
|
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
|
JP4855640B2
(ja)
|
2001-04-02 |
2012-01-18 |
ノヴォ ノルディスク アー／エス |
インシュリン前駆体及びその調製方法
|
|
CN1160122C
(zh)
|
2001-04-20 |
2004-08-04 |
清华大学 |
一种制备口服胰岛素油相制剂的方法
|
|
US20030026872A1
(en)
|
2001-05-11 |
2003-02-06 |
The Procter & Gamble Co. |
Compositions having enhanced aqueous solubility and methods of their preparation
|
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
|
AU2002318159A1
(en)
|
2001-06-29 |
2003-03-03 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
|
FR2827604B1
(fr)
|
2001-07-17 |
2003-09-19 |
Sanofi Synthelabo |
Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
|
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
|
CN1635900A
(zh)
|
2001-08-28 |
2005-07-06 |
伊莱利利公司 |
Glp－1和基础胰岛素的预混合物
|
|
AU2002335046A1
(en)
|
2001-10-19 |
2003-05-06 |
Inhale Therapeutic Systems, Inc. |
The use of proton sequestering agents in drug formulations
|
|
US20050123509A1
(en)
|
2001-10-19 |
2005-06-09 |
Lehrman S. R. |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
|
IL161358A0
(en)
|
2001-11-19 |
2004-09-27 |
Novo Nordisk As |
Process for preparing insulin compounds
|
|
WO2003053363A2
(en)
|
2001-12-19 |
2003-07-03 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
|
|
EP1545460A4
(en)
|
2001-12-20 |
2005-11-16 |
Lilly Co Eli |
INSULIN MOLECULE WITH TEMPORARY EFFECT
|
|
DE60232017D1
(de)
|
2001-12-21 |
2009-05-28 |
Novo Nordisk Healthcare Ag |
Flüssige zusammensetzung aus faktor vii polypeptiden
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
AU2003203146A1
(en)
|
2002-02-07 |
2003-09-02 |
Novo Nordisk A/S |
Use of glp-1 compound for treatment of critically ill patients
|
|
US20100069293A1
(en)
|
2002-02-27 |
2010-03-18 |
Pharmain Corporation |
Polymeric carrier compositions for delivery of active agents, methods of making and using the same
|
|
TWI351278B
(en)
|
2002-03-01 |
2011-11-01 |
Nisshin Pharma Inc |
Agent for preventing and treating of liver disease
|
|
EP1506003A1
(en)
|
2002-05-07 |
2005-02-16 |
Novo Nordisk A/S |
Soluble formulations comprising insulin aspart and insulin detemir
|
|
ATE496064T1
(de)
|
2002-05-07 |
2011-02-15 |
Novo Nordisk As |
Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
|
|
US7115563B2
(en)
|
2002-05-29 |
2006-10-03 |
Insignion Holding Limited |
Composition and its therapeutic use
|
|
US20040022792A1
(en)
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
|
DE10235168A1
(de)
|
2002-08-01 |
2004-02-12 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Reinigung von Preproinsulin
|
|
EP2384750A1
(en)
|
2002-09-27 |
2011-11-09 |
Martek Biosciences Corporation |
Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
|
|
RU2376314C2
(ru)
|
2002-10-02 |
2009-12-20 |
Зилэнд Фарма А/С |
Стабилизированные соединения эксендина-4
|
|
US20050009847A1
(en)
|
2002-11-20 |
2005-01-13 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
CN1413582A
(zh)
|
2002-11-29 |
2003-04-30 |
贵州圣济堂制药有限公司 |
盐酸二甲双胍肠溶片及其制备方法
|
|
AU2003283216A1
(en)
|
2002-12-03 |
2004-06-23 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
|
GB0309154D0
(en)
|
2003-01-14 |
2003-05-28 |
Aventis Pharma Inc |
Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
|
|
GB0304822D0
(en)
|
2003-03-03 |
2003-04-09 |
Dca Internat Ltd |
Improvements in and relating to a pen-type injector
|
|
KR20060015469A
(ko)
|
2003-03-04 |
2006-02-17 |
더 테크놀로지 디벨로프먼트 컴퍼니 리미티드 |
경구용 인슐린 조성물 및 그 제조방법 및 사용방법
|
|
AU2004218808A1
(en)
|
2003-03-11 |
2004-09-23 |
Novo Nordisk A/S |
Pharmaceutical preparations comprising acid-stabilised insulin
|
|
US20040186046A1
(en)
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
|
CA2518776A1
(en)
|
2003-04-29 |
2004-11-11 |
Eli Lilly And Company |
Insulin analogs having protracted time action
|
|
MXPA05013048A
(es)
|
2003-06-03 |
2006-03-02 |
Novo Nordisk As |
Composiciones peptodicas farmaceuticas estabilizadas.
|
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
|
US20050106147A1
(en)
|
2003-08-29 |
2005-05-19 |
Robert Jordan |
Method of promoting graft survival with anti-tissue factor antibodies
|
|
JP5518282B2
(ja)
|
2003-09-01 |
2014-06-11 |
ノヴォ ノルディスク アー／エス |
安定なペプチドの製剤
|
|
WO2005023291A2
(en)
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Use of glp1-agonists in the treatment of patients with type i diabetes
|
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
EP1684793B1
(en)
|
2003-11-13 |
2011-09-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
WO2005048950A2
(en)
|
2003-11-17 |
2005-06-02 |
Biomune, Inc. |
Tumor and infectious disease therapeutic compositions
|
|
JP2007515235A
(ja)
|
2003-12-22 |
2007-06-14 |
ノボ・ノルデイスク・エー／エス |
医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
WO2005067898A2
(en)
|
2004-01-07 |
2005-07-28 |
Nektar Therapeutics |
Improved sustained release compositions for pulmonary administration of insulin
|
|
US20070027063A1
(en)
|
2004-01-12 |
2007-02-01 |
Mannkind Corporation |
Method of preserving the function of insulin-producing cells
|
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
|
US20080248999A1
(en)
|
2007-04-04 |
2008-10-09 |
Biodel Inc. |
Amylin formulations
|
|
JP2008537873A
(ja)
|
2004-03-31 |
2008-10-02 |
セントカー・インコーポレーテツド |
ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
|
|
JP5000493B2
(ja)
|
2004-05-20 |
2012-08-15 |
ディアメディカ インコーポレイテッド |
インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット
|
|
EP1750750B1
(en)
|
2004-06-01 |
2012-02-01 |
Ares Trading S.A. |
Method of stabilizing proteins
|
|
BRPI0512535A
(pt)
|
2004-06-24 |
2008-03-25 |
Incyte Corp |
compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
|
|
US20090042781A1
(en)
|
2004-06-28 |
2009-02-12 |
Novo Nordisk A/S |
Methods for Treating Diabetes
|
|
MX2007000728A
(es)
|
2004-07-21 |
2007-03-15 |
Ambrx Inc |
Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
|
|
AU2005271526B2
(en)
|
2004-08-03 |
2011-12-08 |
Emisphere Technologies, Inc. |
Antidiabetic oral insulin-biguanide combination
|
|
EP1778839B1
(en)
|
2004-08-13 |
2008-07-09 |
Roche Diagniostics GMBH |
C-terminal modification of polypeptides
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
|
US20080280814A1
(en)
|
2004-09-17 |
2008-11-13 |
Novo Nordisk A/S |
Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
|
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−２組成物
|
|
JP5248113B2
(ja)
|
2004-11-12 |
2013-07-31 |
ノヴォ ノルディスク アー／エス |
ペプチドの安定な処方
|
|
RU2413530C9
(ru)
|
2004-11-12 |
2021-05-18 |
Ново Нордиск А/С |
Стабильные препараты инсулинотропных пептидов
|
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
|
SE0402976L
(sv)
|
2004-12-03 |
2006-06-04 |
Mederio Ag |
Medicinsk produkt
|
|
WO2007046834A2
(en)
|
2004-12-22 |
2007-04-26 |
Centocor, Inc. |
Glp-1 agonists, compositions, methods and uses
|
|
US7879361B2
(en)
|
2005-01-04 |
2011-02-01 |
Gp Medical, Inc. |
Nanoparticles for drug delivery
|
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
|
US20080200383A1
(en)
|
2005-04-08 |
2008-08-21 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
|
|
EP1888118B1
(en)
|
2005-05-25 |
2016-08-17 |
Novo Nordisk A/S |
Polypeptide formulations stabilized with ethylenediamine
|
|
ES2399645T3
(es)
|
2005-06-06 |
2013-04-02 |
Camurus Ab |
Formulaciones de análogos de GLP-1
|
|
WO2007001150A2
(en)
|
2005-06-27 |
2007-01-04 |
Jae-Kwan Hwang |
Method for preventing and treating conditions mediated by ppar using macelignan
|
|
US20080227847A1
(en)
|
2005-07-07 |
2008-09-18 |
Aditech Pharma Ab |
Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
|
|
HRP20150186T1
(hr)
|
2005-08-19 |
2015-05-22 |
Amylin Pharmaceuticals, Llc. |
Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
|
|
EP1937297A2
(en)
|
2005-09-08 |
2008-07-02 |
Gastrotech Pharma A/S |
Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
|
|
ES2370657T3
(es)
|
2005-09-14 |
2011-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Escisión de precursores de insulinas mediante una variante de tripsina.
|
|
KR101368525B1
(ko)
|
2005-09-20 |
2014-03-06 |
노파르티스 아게 |
저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도
|
|
US20070078510A1
(en)
|
2005-09-26 |
2007-04-05 |
Ryan Timothy R |
Prosthetic cardiac and venous valves
|
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
|
US8084420B2
(en)
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
|
EP1933884B1
(en)
|
2005-10-11 |
2017-09-06 |
Huntington Medical Research Institutes |
Imaging agents and methods of use thereof
|
|
JP5030960B2
(ja)
|
2005-10-24 |
2012-09-19 |
ネステク ソシエテ アノニム |
食物繊維製剤及び投与方法
|
|
BRPI0520704A2
(pt)
|
2005-11-30 |
2009-05-19 |
Generex Pharm Inc |
formulação farmacêutica absorvida oralmente e método de administração
|
|
US20100029558A1
(en)
|
2005-12-06 |
2010-02-04 |
Bristow Cynthia L |
Alpha1 proteinase inhibitor peptides methods and use
|
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
|
WO2007081792A2
(en)
|
2006-01-05 |
2007-07-19 |
University Of Utah Research Foundation |
Methods and compositions related to improving properties of pharmacological agents targeting nervous system
|
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
|
US20090324701A1
(en)
|
2006-01-20 |
2009-12-31 |
Diamedica, Inc. |
Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
|
|
US20070191271A1
(en)
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
|
EP1986674A4
(en)
|
2006-02-13 |
2009-11-11 |
Nektar Therapeutics |
PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
|
|
US7763582B2
(en)
|
2006-02-21 |
2010-07-27 |
University Of Medicine And Dentistry Of New Jersey |
Localized insulin delivery for bone healing
|
|
WO2007104786A1
(en)
|
2006-03-15 |
2007-09-20 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
WO2007113205A1
(en)
|
2006-04-03 |
2007-10-11 |
Novo Nordisk A/S |
Glp-1 peptide agonists
|
|
CN101454019A
(zh)
|
2006-04-12 |
2009-06-10 |
百达尔公司 |
速效和长效胰岛素联合制剂
|
|
CN101466394A
(zh)
|
2006-04-13 |
2009-06-24 |
科学研究和应用咨询股份公司 |
hGLP-1、胰高血糖素样肽的抑制剂-4及其类似物的药物组合物
|
|
CA2652989A1
(en)
|
2006-06-08 |
2007-12-13 |
Diabecore Medical Inc. |
Derivatized insulin oligomers
|
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
|
US8900555B2
(en)
|
2006-07-27 |
2014-12-02 |
Nektar Therapeutics |
Insulin derivative formulations for pulmonary delivery
|
|
CA2660835A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable propperties
|
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
|
ES2601839T3
(es)
|
2006-09-22 |
2017-02-16 |
Novo Nordisk A/S |
Análogos de insulina resistentes a proteasas
|
|
CN104000779A
(zh)
|
2007-04-23 |
2014-08-27 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
|
WO2008145323A1
(en)
|
2007-05-31 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for interferons
|
|
DK2167169T4
(en)
|
2007-06-14 |
2016-05-30 |
Sanofi Aventis Deutschland |
Tokammerkarpule with accessories
|
|
CN101678174A
(zh)
|
2007-06-14 |
2010-03-24 |
塞诺菲-安万特德国有限公司 |
双室卡普耳
|
|
DK2173407T3
(da)
|
2007-07-02 |
2020-04-27 |
Hoffmann La Roche |
Anordning til indgivelse af lægemiddel
|
|
AU2008287063B2
(en)
|
2007-08-09 |
2013-10-24 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
CN101778862B
(zh)
|
2007-08-13 |
2014-12-17 |
诺沃-诺迪斯克有限公司 |
快速作用的胰岛素类似物
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
GB0717388D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
US20100204117A1
(en)
|
2007-09-11 |
2010-08-12 |
Dorian Bevec |
Cgrp as a therapeutic agent
|
|
US20090104210A1
(en)
|
2007-10-17 |
2009-04-23 |
Tota Michael R |
Peptide compounds for treating obesity and insulin resistance
|
|
RS52566B
(sr)
|
2007-11-01 |
2013-04-30 |
Merck Serono S.A. |
Tečne formulacije lh
|
|
WO2009060071A1
(en)
|
2007-11-08 |
2009-05-14 |
Novo Nordisk A/S |
Insulin derivative
|
|
CA2705821A1
(en)
|
2007-11-16 |
2009-05-22 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and an insulinotropic peptide
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
EP2231191A2
(en)
|
2007-12-11 |
2010-09-29 |
ConjuChem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
|
CN101951957A
(zh)
|
2008-01-04 |
2011-01-19 |
百达尔公司 |
胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
|
|
CN101970476B
(zh)
|
2008-01-09 |
2014-08-27 |
塞诺菲-安万特德国有限公司 |
具有超延迟时效特征的胰岛素衍生物
|
|
AU2009203809B2
(en)
|
2008-01-09 |
2013-07-25 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
KR101573773B1
(ko)
|
2008-02-08 |
2015-12-02 |
바이오제너릭스 게엠베하 |
Ｆｓｈ의 액체 포뮬레이션
|
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
MY161892A
(en)
|
2008-02-19 |
2017-05-15 |
Biocon Ltd |
A method of obtaining a purified, biologically active heterologous protein
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
WO2009143014A1
(en)
|
2008-05-23 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
JP2011526303A
(ja)
|
2008-06-27 |
2011-10-06 |
デューク ユニバーシティ |
エラスチン様ペプチドを含む治療剤
|
|
US7986407B2
(en)
|
2008-08-04 |
2011-07-26 |
Ondax, Inc. |
Method and apparatus using volume holographic wavelength blockers
|
|
JP5854836B2
(ja)
|
2008-08-30 |
2016-02-09 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
カートリッジ及びそのための針システム
|
|
WO2010028055A1
(en)
|
2008-09-02 |
2010-03-11 |
Biodel, Inc. |
Insulin with a basal release profile
|
|
WO2010030670A2
(en)
|
2008-09-10 |
2010-03-18 |
Genentech, Inc. |
Compositions and methods for the prevention of oxidative degradation of proteins
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
US20100092566A1
(en)
|
2008-10-15 |
2010-04-15 |
Alessi Thomas R |
Highly concentrated drug particles, formulations, suspensions and uses thereof
|
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
HUE068164T2
(hu)
|
2008-10-17 |
2024-12-28 |
Sanofi Aventis Deutschland |
Egy inzulin és egy GLP-1 agonista kombinációja
|
|
WO2010049488A1
(en)
|
2008-10-30 |
2010-05-06 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Ｐｔｈの安定化水溶液注射剤
|
|
AR075204A1
(es)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
|
|
CA2750049C
(en)
|
2009-02-04 |
2021-02-23 |
Sanofi-Aventis Deutschland Gmbh |
Medical device and method for providing information for glycemic control
|
|
MX2011008416A
(es)
|
2009-02-13 |
2011-09-08 |
Boehringer Ingelheim Int |
Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
|
|
WO2010138671A1
(en)
|
2009-05-28 |
2010-12-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
US20120232002A1
(en)
|
2009-07-06 |
2012-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Slow-acting insulin preparations
|
|
JP2012532177A
(ja)
|
2009-07-06 |
2012-12-13 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
熱及び振動安定性インスリン製剤
|
|
WO2011003822A2
(de)
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Insulinzubereitungen enthaltend methionin
|
|
US8709400B2
(en)
|
2009-07-27 |
2014-04-29 |
Washington University |
Inducement of organogenetic tolerance for pancreatic xenotransplant
|
|
SG178195A1
(en)
|
2009-07-31 |
2012-03-29 |
Sanofi Aventis Deutschland |
Long acting insulin composition
|
|
US8642548B2
(en)
|
2009-08-07 |
2014-02-04 |
Mannkind Corporation |
Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
PL2324853T3
(pl)
|
2009-11-13 |
2016-01-29 |
Sanofi Aventis Deutschland |
Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
|
|
CA2780460C
(en)
|
2009-11-13 |
2018-09-04 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
RS52629B2
(sr)
|
2009-11-13 |
2019-11-29 |
Sanofi Aventis Deutschland |
Liksisenatid kao dodatna terapija insulin glarginu i metforminu za lečenje dijabetesa tipa 2
|
|
CA2685638C
(en)
|
2009-11-13 |
2017-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
US20110118178A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
SG10201500871TA
(en)
|
2009-11-13 |
2015-04-29 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
EA201201164A1
(ru)
|
2010-02-22 |
2013-04-30 |
Кейз Вестерн Ризев Юнивесити |
Препараты на основе аналогов инсулина пролонгированного действия в растворимой и кристаллической формах
|
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
|
AR080884A1
(es)
|
2010-04-14 |
2012-05-16 |
Sanofi Aventis |
Conjugados de insulina-sirna
|
|
US8637458B2
(en)
|
2010-05-12 |
2014-01-28 |
Biodel Inc. |
Insulin with a stable basal release profile
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
WO2011144674A2
(en)
|
2010-05-20 |
2011-11-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
|
|
EP2389945A1
(en)
*
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
|
US9085757B2
(en)
|
2010-06-17 |
2015-07-21 |
Regents Of The University Of Minnesota |
Production of insulin producing cells
|
|
US8532933B2
(en)
|
2010-06-18 |
2013-09-10 |
Roche Diagnostics Operations, Inc. |
Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
RS55378B1
(sr)
|
2010-08-30 |
2017-03-31 |
Sanofi Aventis Deutschland |
Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
|
|
RS59423B1
(sr)
|
2010-10-27 |
2019-11-29 |
Novo Nordisk As |
Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
|
|
WO2012065996A1
(en)
|
2010-11-15 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
|
|
WO2012066086A1
(en)
|
2010-11-17 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
|
|
CN103249427A
(zh)
|
2010-12-14 |
2013-08-14 |
诺沃—诺迪斯克有限公司 |
速效胰岛素联合长效胰岛素
|
|
RU2572703C2
(ru)
|
2011-02-02 |
2016-01-20 |
Санофи-Авентис Дойчланд Гмбх |
Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа
|
|
HUE065915T2
(hu)
|
2011-03-11 |
2024-06-28 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antitestek és alkalmazásaik
|
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
|
BR112013029062A2
(pt)
|
2011-05-13 |
2016-11-29 |
Sanofi Aventis Deutschland |
lixisenatida e metformina para o tratamento de diabetes tipo 2
|
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
|
US9821032B2
(en)
*
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
EP2723359A4
(en)
|
2011-06-24 |
2015-03-11 |
Amylin Pharmaceuticals Llc |
METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS
|
|
BR112014004726A2
(pt)
|
2011-08-29 |
2017-04-04 |
Sanofi Aventis Deutschland |
combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
US20130096060A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
|
|
EP2763691A1
(en)
|
2011-10-04 |
2014-08-13 |
Sanofi-Aventis Deutschland GmbH |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
|
JP6329487B2
(ja)
|
2011-10-28 |
2018-05-23 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
２型糖尿病の治療プロトコル
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
US9522235B2
(en)
|
2012-05-22 |
2016-12-20 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
|
|
DK2968471T3
(en)
|
2013-03-01 |
2017-10-23 |
Fundació Hospital Univ Vall D' Hebron - Inst De Recerca |
Peptides for use in the topical treatment of retinal neurodegenerative diseases, especially in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
|
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
|
DK3010530T3
(en)
|
2013-06-17 |
2019-04-15 |
Sanofi Aventis Deutschland |
FIXED-FORMULATED FORMULATION BETWEEN INSULIN GLARGIN AND LIXISENATIDE
|
|
TW201605489A
(zh)
|
2013-10-25 |
2016-02-16 |
賽諾菲公司 |
賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
|
|
TWI758239B
(zh)
|
2014-12-12 |
2022-03-21 |
德商賽諾菲阿凡提斯德意志有限公司 |
甘精胰島素/利司那肽固定比率配製劑
|
|
TWI706779B
(zh)
|
2015-01-16 |
2020-10-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
小兒第２型糖尿病病患之治療
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
US10905707B2
(en)
|
2017-11-10 |
2021-02-02 |
University Of Massachusetts |
Compositions and methods for the treatment of expanded repeat-associated disorders
|